PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
NERVOUS SYSTEM ANTIPSYCHOTIC TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS INVERSE AGONIST / ANTAGONIST SEROTONIN 5-HT2A (KI = 0.087 NANOMOLAR) AND 5-HT2C (KI = 0.44 NANOMOLAR) SIGMA 1 RECEPTOR (KI = 120 NANOMOLAR)
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
NERVOUS SYSTEM ANTIPSYCHOTIC TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS INVERSE AGONIST / ANTAGONIST SEROTONIN 5-HT2A (KI = 0.087 NANOMOLAR) AND 5-HT2C (KI = 0.44 NANOMOLAR) SIGMA 1 RECEPTOR (KI = 120 NANOMOLAR)